Psychiatry and Neurology, Neurology · Commack, NY
NPI
1427056605
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
283 Commack Rd, Suite 101
Commack, NY, 11725
Phone (631) 462-7774
Groups this clinician bills Medicare through
Medicare paid, 2024
$154K
1,920 services
Medicare patients, 2024
474
Average age 78
Drug cost, 2024
$3.2M
5,065 prescriptions
Company payments, 2025
$380K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David L Kreitzman was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 539 times for 234 patients. In total David L Kreitzman billed 1,920 services in 12 codes, and Medicare paid $154K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-04-02.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 539 | 234 | $13.58 | $7,317 |
| 99215 Office E&M - Established | Office | 506 | 217 | $144.64 | $73K |
| 99215 Office E&M - Established | Facility | 277 | 154 | $120.26 | $33K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 208 | 150 | $14.41 | $2,997 |
| 99214 Office E&M - Established | Office | 118 | 67 | $96.41 | $11K |
| 99205 Office E&M - New | Office | 75 | 75 | $177.96 | $13K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 62 | 62 | $27.45 | $1,702 |
| 99214 Office E&M - Established | Facility | 57 | 39 | $81.32 | $4,635 |
| 99205 Office E&M - New | Facility | 28 | 28 | $155.98 | $4,367 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 23 | 23 | $27.90 | $642 |
By year: 2022 $166K for 1,195 services; 2023 $154K for 1,160 services; 2024 $154K for 1,920 services.
Medicare prescription drug claims, 2024
In 2024, the drug David L Kreitzman prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 1,166 prescriptions and refills. In total David L Kreitzman wrote 5,065 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 1,166 | 2,462 | 290 | $34K |
| Rytary Carbidopa/Levodopa | 730 | 964 | 106 | $759K |
| Rasagiline Mesylate Generic | 597 | 1,329 | 138 | $156K |
| Ongentys Opicapone | 300 | 334 | 40 | $222K |
| Nuplazid Pimavanserin Tartrate | 253 | 277 | 31 | $1.3M |
| Escitalopram Oxalate Generic | 234 | 505 | 61 | $2,793 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 186 | 400 | 54 | $3,998 |
| Amantadine Amantadine Hcl | 170 | 282 | 36 | $7,403 |
| Donepezil Hcl Generic | 166 | 360 | 40 | $1,729 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 120 | 280 | 27 | $2,090 |
| Mirtazapine Generic | 111 | 267 | 32 | $2,418 |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 93 | 165 | 20 | $31K |
| Selegiline Hcl Generic | 91 | 177 | 19 | $6,933 |
| Gocovri Amantadine Hcl | 81 | 89 | Under 11 | $211K |
| Rivastigmine Generic | 72 | 152 | 21 | $16K |
Brand drugs: 1,898 claims; generic drugs: 3,167 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David L Kreitzman $380K ($257K in general payments such as food, travel and fees and $123K for research) from 6 companies. The largest payer was Amneal Pharmaceuticals LLC with $184K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.